Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.1056/nejmoa052306 | Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer |
| https://doi.org/10.1093/annonc/mdu450 | The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 |
| https://doi.org/10.1056/nejmoa1602253 | 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer |
| https://doi.org/10.1056/nejmoa2105215 | Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer |
| https://doi.org/10.1056/nejmoa1703643 | Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer |
| https://doi.org/10.1016/s0140-6736(11)61847-3 | Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial |
| https://doi.org/10.1097/pap.0000000000000161 | Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors |
| https://doi.org/10.1097/pap.0000000000000162 | Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research |
| https://doi.org/10.1038/nrclinonc.2015.73 | Clinical management of breast cancer heterogeneity |
| https://doi.org/10.1016/s1470-2045(13)70048-2 | Planning cancer control in Latin America and the Caribbean |
| https://doi.org/10.1016/j.annonc.2022.09.159 | Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer |
| https://doi.org/10.1093/annonc/mdx651 | Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program |
| https://doi.org/10.1016/j.ctrv.2013.03.009 | Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer |
| https://doi.org/10.1200/jco.20.01204 | Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up |
| https://doi.org/10.1016/s1470-2045(21)00007-3 | 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age |
| https://doi.org/10.1038/s41571-018-0089-9 | Progress in adjuvant systemic therapy for breast cancer |
| https://doi.org/10.1016/s1470-2045(20)30642-2 | Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study |
| https://doi.org/10.1038/ncponc0591 | Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial |
| https://doi.org/10.1200/jco.21.02554 | Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) |
| https://doi.org/10.1093/annonc/mdr352 | Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries |
| https://doi.org/10.1056/nejmoa2212856 | Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer |
| https://doi.org/10.1093/annonc/mdn005 | Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial |
| https://doi.org/10.1007/s10549-010-0761-y | Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers |
| https://doi.org/10.1158/2159-8290.cd-20-1647 | Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative |
| https://doi.org/10.1093/annonc/mds328 | Pertuzumab: new hope for patients with HER2-positive breast cancer |
| https://doi.org/10.1007/s10549-009-0512-0 | The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial |
| https://doi.org/10.2967/jnumed.112.119271 | 18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO |
| https://doi.org/10.1200/jco.2014.32.18_suppl.lba4 | First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). |
| https://doi.org/10.1016/j.ctrv.2016.08.008 | Endocrine treatment in breast cancer: Cure, resistance and beyond |
| https://doi.org/10.1158/0008-5472.sabcs10-s3-3 | Abstract S3-3: First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer |
| https://doi.org/10.1158/1078-0432.ccr-16-0979 | The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data |
| https://doi.org/10.1016/j.ctrv.2017.04.005 | Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials |
| https://doi.org/10.1016/j.ejca.2017.08.020 | Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE) |
| https://doi.org/10.1093/jnci/djy094 | Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients |
| https://doi.org/10.1016/s1470-2045(16)30099-7 | Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials |
| https://doi.org/10.1016/s1470-2045(19)30334-1 | Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial |
| https://doi.org/10.1016/j.ejca.2019.04.038 | Survival outcomes of the NeoALTTO study (BIG 1–06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer |
| https://doi.org/10.1038/bjc.2014.341 | The AURORA initiative for metastatic breast cancer |
| https://doi.org/10.1002/path.4540 | Uncovering the genomic heterogeneity of multifocal breast cancer |
| https://doi.org/10.1002/cncr.31784 | Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO (BIG 1‐06) and ALTTO (BIG 2‐06) trials |
| https://doi.org/10.1007/s10549-019-05453-z | A pooled analysis of the cardiac events in the trastuzumab adjuvant trials |
| https://doi.org/10.1200/jco.2020.38.15_suppl.506 | MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients. |
| https://doi.org/10.1200/jco.20.01382 | Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors |
| https://doi.org/10.1093/annonc/mdh062 | Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG) |
| https://doi.org/10.1093/annonc/mdw132 | Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer |
| https://doi.org/10.1158/1078-0432.ccr-19-1164 | Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study |
| https://doi.org/10.1200/po.20.00345 | Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer |
| https://doi.org/10.1016/j.annonc.2022.06.009 | VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up |
| https://doi.org/10.1158/1078-0432.ccr-21-0310 | Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study |
| https://doi.org/10.1158/1538-7445.sabcs17-gs2-06 | Abstract GS2-06: Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/BIG 4-13/KEYNOTE-014) study |
| https://doi.org/10.14694/edbook_am.2015.35.e183 | Clinical Trials of Precision Medicine through Molecular Profiling: Focus on Breast Cancer |
| https://doi.org/10.1200/jco.21.01918 | Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03) |
| https://doi.org/10.1016/j.annonc.2022.03.008 | VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer |
| https://doi.org/10.1016/j.bja.2022.12.013 | Towards precision pain medicine for pain after cancer: the Cancer Pain Phenotyping Network multidisciplinary international guidelines for pain phenotyping using nociplastic pain criteria |
| https://doi.org/10.1016/s0959-8049(20)30542-6 | Clinical utility of MammaPrint testing in Invasive Lobular Carcinoma: Results from the MINDACT phase III trial |
| https://doi.org/10.1200/jco.23.00126 | Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial |
| https://doi.org/10.1093/jnci/djac126 | Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab |
| https://doi.org/10.1001/jama.2024.26886 | Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer |
| https://doi.org/10.6004/jnccn.2022.7065 | Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer |
| https://doi.org/10.1001/jamaoncol.2023.7304 | Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer |
| https://doi.org/10.1200/jco.23.02505 | Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update |
| https://doi.org/10.3390/nu16172908 | The Dairy Matrix: Its Importance, Definition, and Current Application in the Context of Nutrition and Health |
| https://doi.org/10.1038/s41467-024-54621-3 | Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial |
| https://doi.org/10.1200/jco.23.01214 | Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer |
| https://doi.org/10.1001/jamasurg.2025.3600 | Diagnostic Accuracy of Imaging in Assessing Nonviability of Disappearing Colorectal Liver Metastasis |
| https://doi.org/10.1016/j.annonc.2025.08.725 | 296O Risk of recurrence (ROR) after neoadjuvant ribociclib plus ET in clinically high-risk ER+/HER2− BC: Preliminary analysis of the SOLTI-RIBOLARIS trial |
| https://doi.org/10.1001/jamaoncol.2016.0339 | Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab |
| https://doi.org/10.1016/j.maturitas.2008.12.002 | Breast cancer seeding associated with core needle biopsies: A systematic review |
| https://doi.org/10.1016/s1470-2045(11)70378-3 | A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints |
| https://doi.org/10.1016/s0960-9776(11)70289-2 | Beyond trastuzumab: New treatment options for HER2-positive breast cancer |
| https://doi.org/10.1177/1758835919827714 | Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives |
| https://doi.org/10.1146/annurev-med-051413-024741 | Neoadjuvant Therapy for Breast Cancer |
| https://doi.org/10.1186/1471-2164-15-1008 | Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology |
| https://doi.org/10.1007/s10549-017-4628-3 | Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06) |
| https://doi.org/10.1039/c8se00085a | The biologically mediated water–gas shift reaction: structure, function and biosynthesis of monofunctional [NiFe]-carbon monoxide dehydrogenases |
| https://doi.org/10.1093/annonc/mdw286 | Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers |
| https://doi.org/10.1158/1078-0432.ccr-18-2507 | Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial |
| https://doi.org/10.3332/ecancer.2017.746 | The past and future of breast cancer treatment—from the papyrus to individualised treatment approaches |
| https://doi.org/10.1016/j.ejca.2016.04.024 | Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial |
| https://doi.org/10.1186/1471-2407-12-495 | Health-related quality of life in survivors of stage I-II breast cancer: randomized trial of post-operative conventional radiotherapy and hypofractionated tomotherapy |
| https://doi.org/10.1200/jco.2019.37.15_suppl.1012 | Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial. |
| https://doi.org/10.1097/cco.0b013e328358a2b5 | Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition |
| https://doi.org/10.1136/jmedgenet-2019-106072 | Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1/2breast cancer families |
| https://doi.org/10.1007/s10549-019-05284-y | Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial |
| https://doi.org/10.3390/ijms21041386 | Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy |
| https://doi.org/10.1200/jco.2014.32.15_suppl.lba4 | First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). |
| https://doi.org/10.1371/journal.pone.0154009 | Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer |
| https://doi.org/10.1038/s41416-020-0786-x | Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial |
| https://doi.org/10.1158/1538-7445.sabcs19-gs1-04 | Abstract GS1-04: Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer |
| https://doi.org/10.1158/1078-0432.ccr-21-2103 | Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer |
| https://doi.org/10.1200/jco.2021.39.15_suppl.lba1 | OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer. |
| https://doi.org/10.1016/j.ejca.2017.04.014 | Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper |
| https://doi.org/10.1186/s13058-020-01356-w | Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial |
| https://doi.org/10.1158/1078-0432.ccr-17-3473 | Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study |
| https://doi.org/10.1136/esmoopen-2020-000842 | Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis |
| https://doi.org/10.1016/j.annonc.2020.08.2240 | LBA12 PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer |
| https://doi.org/10.1016/j.annonc.2021.05.804 | Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust |
| https://doi.org/10.1016/j.ejca.2021.01.053 | Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D) |
| https://doi.org/10.1186/bcr3142 | Targeted therapies in breast cancer: are heart and vessels also being targeted? |
| https://doi.org/10.1039/c8cc04366c | MRI and luminescence detection of Zn2+ with a lanthanide complex–zinc finger peptide conjugate |